U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
17. April 2024 08:00 ET
|
Kaléo
Richmond, Virginia, April 17, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development...
Kaléo Expands Executive Team to Support Growth
27. Juni 2023 08:00 ET
|
Kaléo
Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today...
Kaléo Expands Executive Team to Support Growth
27. Juni 2023 08:00 ET
|
Kaléo
Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today...
Kaléo Adds Chief Business Officer to Executive Team
27. September 2022 08:00 ET
|
Kaléo
Richmond, VA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today...
Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
21. September 2022 08:00 ET
|
Kaléo
Richmond, VA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kaléo, a privately held commercial-stage U.S. pharmaceutical company, today announced the execution of the first contract with the U.S. Department of...
Kaléo Announces Executive Appointments and New Government Business Unit
11. August 2022 08:25 ET
|
Kaléo
Richmond, VA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products for certain...